News
01-29-2009, 10:11 AM
Recent studies suggest that human breast cancer risk is increased by outside exposure to the hormone progestin, such as during hormone replacement therapy. Now, a University of Missouri study suggests that PRIMA-1, a small molecule drug that targets the most common mutated gene, p53, in human cancer cells, has potential as a novel chemotherapeutic treatment for progestin-accelerated human breast cancer.
More... (http://www.medicalnewstoday.com/articles/137167.php)
More... (http://www.medicalnewstoday.com/articles/137167.php)